Keyword: Pfizer

Eli Lilly and Pfizer’s nonopioid NGF inhibitor tanezumab beat out placebo in a phase 3 study of patients with chronic lower back pain.

Solid Bio’s run of negative news is continuing with another setback for its Duchenne muscular dystrophy gene therapy.

GlaxoSmithKline is cutting a host of unwanted investigational drugs as it joins other Big Pharmas in the fourth-quarter clearout.

Pfizer and Lilly now have two trials showing NGF blocker tanezumab reduces pain in arthritis, but cases of rapid joint damage are still seen.

Pfizer has inked a deal with CytoReason to use its cell-centered models of the immune system for drug discovery.

Allogeneic CAR-T therapy, which uses donor T cells, has the potential to clear the hurdles that come with autologous CAR-T, which uses a patient’s own T cells.